October 2014

South Florida Gala of Hope Closes in on Milestone

On Thursday, October 2, Jennifer Miller Smith and Fiorenna Fuentes Israel, two dedicated mothers of children with SMA, planned an evening to be remembered in their quest to achieve a huge fundraising milestone: $500,000 to cure spinal muscular atrophy. This year’s event, the 4th Annual Gala of Hope, has already raised $110,000 and climbing, bringing […]

South Florida Gala of Hope Closes in on Milestone Read More »

AveXis Announces the Completion of Dosing of the Low-Dose Cohort in US Clinical Trial for Spinal Muscular Atrophy

AveXis, Inc., a clinic-stage gene therapy company, today announced the completion of dosing in the low dose cohort in the world’s first human gene therapy trial for the treatment of infants with spinal muscular atrophy (SMA). The trial (NCT02122952) opened for enrollment in April 2014. “History in gene transfer therapy was made on May 13th,

AveXis Announces the Completion of Dosing of the Low-Dose Cohort in US Clinical Trial for Spinal Muscular Atrophy Read More »

Isis Presents Phase II Trial Results

This Friday, October 10, Isis Pharmaceuticals will be presenting results from their Phase II clinical trials of ISIS-SMNRx in both children and infants. The results will be presented as part of the 19th International World Muscle Society Congress in Berlin, Germany. The presentation is also available via a live streaming webcast and conference call. When:

Isis Presents Phase II Trial Results Read More »

AveXis Receives Orphan Drug Designation

AveXis has received Orphan Drug Designation from the FDA for their gene therapy program, called chariSMA. Orphan Drug Designation is granted by the FDA to encourage and expedite the development of drugs for conditions like SMA. In the chariSMA program, researchers are using the AAV9 virus to “infect” a cell with new DNA from survival

AveXis Receives Orphan Drug Designation Read More »

Isis Begins Recruiting for Phase III Trial

Isis is currently recruiting participants for Endear, a pivotal Phase III study evaluating ISIS-SMNRx in infants with spinal muscular atrophy (SMA). The goal of this Phase III trial is to assess the clinical efficacy and safety of ISIS-SMNRx administered intrathecally (through an injection in the lower back, similar to an epidural) in patients with SMA.

Isis Begins Recruiting for Phase III Trial Read More »

Cole P Randall Memorial Golf Tournament Raises $75,000

The Inaugural Cole P Randall Memorial Golf Tournament was held on Saturday, September 27, at The Reserve Vineyards and Golf Club in Portland, OR. This fun event had a full flight of golfers, supporters, and friends enjoying a day of SMA awareness on the greens, followed by an incredible evening of cocktails, dinner, dancing, and

Cole P Randall Memorial Golf Tournament Raises $75,000 Read More »

Cure SMA-Funded CALIBR Research Collaboration Expanded to USC

Cure SMA is pleased to announce that we have expanded our research collaboration with the California Institute for Biomedical Research (CALIBR) to include a collaborative effort with Dr. Chien-Ping Ko of the University of Southern California. At Cure SMA, we know that no single group can develop a treatment for SMA alone—it requires collaboration. One

Cure SMA-Funded CALIBR Research Collaboration Expanded to USC Read More »

Scroll to Top